Key result
Baseline dietary sodium intake shows no association with composite cardiovascular events or mortality.
Why the study?
Evidence from the SODIUM-HF trial and a meta-analysis failed to show a beneficial effect of dietary sodium restriction on heart failure outcomes, prompting further analysis of sodium intake associations.
Is baseline or achieved dietary sodium intake associated with clinical outcomes in patients with heart failure?
Observational (n=792)
Is baseline or achieved dietary sodium intake associated with clinical outcomes in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I usually say things such as restricting sodium in your diet is generally healthy overall and there is certainly no safety issue when you do that. It likely doesn't reduce the risk for needing to be hospitalized or visiting the ER, or dying from heart failure, but it may improve quality of life and it's part of an overall healthier dietary pattern, probably something that could contribute to your overall health.”
“While the intervention didn't reduce clinical events, we found the low-sodium group had modest improvements in quality of life and New York Heart Association heart failure class, which we think will be quite important and valued by patients and clinicians alike. We need to explore further whether there might be a way to individualize recommendations from our trial to see if the quality-of-life benefits might make it worth it for certain patients [to reduce sodium intake].”
“It is important to understand the kinds of patients we are referring to, how advanced they are, and what comorbidities the patients have. We also know that there are race, ethnicity, and gender differences in sensitivity to sodium.”
Baseline dietary sodium intake was not significantly associated with clinical outcomes in heart failure patients, though achieving <1500 mg/day by 6 months showed a trend toward fewer events.
Background Sodium restriction is common advice provided to patients with heart failure, however, evidence from the SODIUM-HF trial and a subsequent meta-analysis failed to show a beneficial effect of dietary sodium restriction on outcomes. Purpose This secondary analysis of SODIUM HF is aimed to assess association between baseline dietary sodium intake, the change in dietary sodium at 6 months and a composite of cardiovascular hospitalization, emergency department visit, and all-cause death at 12 and 24 months. Methods Multivariable Cox proportional hazard regression model was used to assess association of dietary sodium level measured at randomization with primary and secondary endpoints. Adjusted Hazard ratios and 95% confidence intervals were presented. A responder analysis also explored the achieved dietary sodium at 6 months with subsequent risk for clinical outcomes. Results 792 participants were included. At baseline, sodium intake was ≤ 1500 mg/day in 19.9% (n = 158), >1500-3000 mg/day in 56.5% (n = 448) and >3000 mg/day in 23.4% (n= 186) of the participants. Women, older patients, and those with lower glomerular filtration rate and higher ejection fraction were more often represented in the group with sodium intake ≤1500 mg/day; conversely, diabetes, prior smoking, use of mineralocorticoid receptor antagonists, and ICD were observed in the groups of higher sodium intake levels (>3000 mg/day)(Table 1). Cox proportional hazard regression analysis showed no association between sodium level (per doubling) at baseline with clinical outcomes (all associations p=ns), however, adjusted models exhibited a trend towards a decreased risk of CV hospitalizations at 2 years. In the responder analysis, a trend towards a decreased adjusted risk for composite outcome and CV hospitalizations at 1 year in those achieving a sodium level <1500 mg at 6 months was observed (Table 2). Adjusted Cox proportional hazard regression analysis showed no association for 1- and 2-year outcomes per 500 mg increase in absolute difference in sodium level between baseline and 6 months. Conclusion In SODIUM HF, there was no association between sodium level at baseline with clinical outcomes at any time point but there is a trend towards a decreased risk of CV hospitalizations at 2 years and in patients achieving <1500 mg / day by 6 months, a trend towards fewer subsequent clinical events was present. This finding should be explored via a prospective clinical trial.
No takes yet. Share an insight, caveat, or question.
COLINRAMIREZ et al. (2023) conducted an observational in Heart failure (n=792). Dietary sodium intake vs. Different levels of sodium intake was evaluated on Composite of cardiovascular hospitalization, emergency department visit, and all-cause death at 12 and 24 months (p=ns). Baseline dietary sodium intake was not associated with the composite of cardiovascular hospitalization, emergency department visit, and all-cause death at 12 and 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: